查看购物车
  • Traditional Chinese
  • English
  • Japanese
欧洲青光眼治疗市场预测（2031年）-区域分析-依药物类别、适应症及配销通路
市场调查报告书
商品编码
1764897

欧洲青光眼治疗市场预测（2031年）-区域分析-依药物类别、适应症及配销通路

Europe Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 133 Pages | 订单完成后即时交付

价格

2023 年欧洲青光眼治疗市场价值为 15.2983 亿美元，预计到 2031 年将达到 19.3078 亿美元；预计 2023 年至 2031 年的复合年增长率为 3.0%。

越来越多的产品发布、合作和收购推动了欧洲青光眼治疗市场的发展

青光眼治疗药物製造商正在实施策略联盟、地理扩张、合作伙伴关係、併购和产品/服务发布等策略，以彰显其在市场上的地位。

2024 年 3 月，专门从事创新眼部药物传输技术的公司 MediPrint Ophthalmics 宣布成功完成其 2b 期青光眼 SIGHT-2 研究。

2023年12月，美国食品药物管理局（FDA）批准了Glaukos公司iDose TR（曲伏前列素前房植入剂）75微克的新药申请（NDA）。 iDose TR是一种前列腺素类似物，用于降低眼高压症（OHT）或开角型青光眼（OAG）患者的眼压。该药物获准每眼单次给药。

2022年11月，爱尔康收购了Aerie Pharmaceuticals, Inc.。透过此次收购，爱尔康获得了Rocklatan（奈他舒地尔和拉坦前列素滴眼液）0.02%/0.005%；Rhopressa（奈他舒地尔滴眼液）0.02%；AR-15512（用于治疗干眼症的III期候选产品）；以及一系列临床候选药物和临床阶段的临床候选药物。 Rocklatan和Rhopressa皆为Rho激酶抑制剂，用于降低开角型青光眼或高眼压症患者的眼压升高。此次收购使爱尔康在拓展其产品组合方面迈出了一步，将青光眼、视网膜和眼表疾病治疗药物纳入其中。

2022年3月，强生视力保健公司（Johnson & Johnson Vision Care, Inc.）旗下新款ACUVUE Theravision隐形眼镜获得美国食品药品监督管理局（FDA）批准，该款隐形眼镜含有抗组织胺药酮替芬（每片19微克）。含酮替芬的ACUVUE Theravision隐形眼镜是同类产品中的首款产品，旨在为出现过敏性眼痒的隐形眼镜使用者带来全新的配戴体验。此类产品发布、合作和收购对青光眼治疗市场的成长做出了重大贡献。

欧洲青光眼治疗市场概况

欧洲青光眼治疗市场分为德国、法国、英国、西班牙、义大利和欧洲其他地区。德国和义大利等国家为该地区的市场贡献了相当大的份额，而法国、英国和西班牙等国家则可能为青光眼治疗市场参与者带来巨大的成长机会。欧洲青光眼治疗市场的成长归因于随着人口老化加剧，青光眼病例数量不断增加。德国是青光眼发生率较高的国家。根据萨贝尔视力恢復中心 (SAVIR) 的数据，该国约有 50 万人患有青光眼。然而，专家估计，由于未报告的病例，实际数字可能要高得多。近 10% 的青光眼患者最终会出现严重的视力障碍；儘管如此，几乎没有人会完全失明。根据联邦统计局 (Destatis) 的数据，截至 2021 年底，德国 67 岁及以上人口将达到 1,620 万，预计到 2060 年这一数字将增至 2,160 万。随着年龄的增长，患青光眼和其他眼部疾病的机率可能会增加。因此，老年人口激增导致青光眼盛行率大幅上升，从而推动了德国各地对青光眼治疗药物的需求。

欧洲青光眼治疗市场收入及预测（2031年）（百万美元）

欧洲青光眼治疗市场细分

欧洲青光眼治疗市场按药物类别、适应症、配销通路和国家分类。

依药物类别，欧洲青光眼治疗市场细分为β受体阻断剂、α肾上腺素激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物及其他。前列腺素类似物在2023年占据了最大的市场。

根据适应症，欧洲青光眼治疗市场分为开角型青光眼、闭角型青光眼和其他类型。 2023年，开角型青光眼占了最大的市场。

根据配销通路，欧洲青光眼治疗市场分为医院药房、零售药房和线上药房。 2023年，医院药局占了最大的市场份额。

按国家/地区划分，欧洲青光眼治疗市场分为德国、法国、义大利、英国、西班牙和欧洲其他地区。 2023年，德国占据了欧洲青光眼治疗市场的主导地位。

Alcon AG、AbbVie Inc、Bausch & Lomb Inc, LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc 和 Santen Pharmaceutical Co., Ltd. 是欧洲青光眼治疗市场的主要公司。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第四章：欧洲青光眼治疗市场-关键市场动态

  • 青光眼治疗市场－关键市场动态
  • 市场驱动因素
    • 青光眼发生率不断上升
    • 产品发布、合作和收购的数量不断增加
  • 市场限制
    • 药物治疗方案依从性问题
  • 市场机会
    • 穿戴式科技的发展
  • 未来趋势
    • 新型药物输送方法的开发
  • 驱动因素和限制因素的影响：

第五章：青光眼治疗市场－欧洲分析

  • 2021-2031年青光眼治疗市场收入
  • 青光眼治疗市场预测分析

第六章：欧洲青光眼治疗市场分析－依药物类别

  • β受体阻断剂
  • α肾上腺素激动剂
  • 前列腺素类似物
  • 碳酸酐酶抑制剂
  • 联合用药
  • 其他的

第七章：欧洲青光眼治疗市场分析－按适应症

  • 开角型青光眼
  • 闭角型青光眼
  • 其他的

第八章：欧洲青光眼治疗市场分析－按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第九章：欧洲青光眼治疗市场-国家分析

  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区

第 10 章：青光眼治疗市场-产业格局

  • 青光眼治疗市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 11 章：公司简介

  • Alcon AG
  • AbbVie Inc
  • Bausch & Lomb Inc
  • Viatris Inc
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Thea Pharma Inc
  • Santen Pharmaceutical Co., Ltd.

第 12 章：附录

Product Code: BMIRE00031611

The Europe glaucoma therapeutics market was valued at US$ 1,529.83 million in 2023 and is expected to reach US$ 1,930.78 million by 2031; it is estimated to register a CAGR of 3.0% from 2023 to 2031.

Increasing Number of Product Launches, Collaborations, and Acquisitions Fuels Europe Glaucoma Therapeutics Market

Glaucoma therapeutics manufacturers are implementing strategies such as strategic alliances, geographic expansions, partnerships, mergers & acquisitions, and product/service launches to mark their presence in the market.

In March 2024, MediPrint Ophthalmics, a company that specializes in innovative ocular drug delivery technologies, announced the successful completion of its Phase 2b Glaucoma SIGHT-2 study.

In December 2023, the US Food and Drug Administration (FDA) approved Glaukos Corporation's New Drug Application (NDA) for iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of IOP in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). The drug was approved for a single administration per eye.

In November 2022, Alcon acquired Aerie Pharmaceuticals, Inc. Through the transaction, Alcon acquired Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%; Rhopressa (netarsudil ophthalmic solution) 0.02%; AR-15512, a Phase 3 product candidate for dry eye disease; and a pipeline of several preclinical and clinical ophthalmic pharmaceutical product candidates. Rocklatan and Rhopressa are Rho-kinase inhibitors indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. With this acquisition, Alcon takes a step forward to broaden its portfolio with the inclusion of glaucoma, and retinal and ocular surface disease therapeutics.

In March 2022, Johnson & Johnson Vision Care, Inc. received FDA approval for its new ACUVUE Theravision variant, a type of contact lens containing an antihistamine called ketotifen (19 µg per lens). ACUVUE Theravision with Ketotifen is the first of its kind and is designed to provide a new wearing experience for contact lens users, experiencing allergic eye itch. Such product launches, collaborations, and acquisitions contribute significantly to the growth of the glaucoma therapeutics market.

Europe Glaucoma Therapeutics Market Overview

The Europe glaucoma therapeutics market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy contribute significant shares to the market in this region, and countries such as France, the UK, and Spain are likely to present significant growth opportunities for glaucoma therapeutics market players. The Europe glaucoma therapeutics market growth is ascribed to the rising number of glaucoma cases with the increasing aging population. Germany records a widespread occurrence of glaucoma. According to Sabel Vision Restoration Center (SAVIR), approximately half a million people are affected by glaucoma in this country. However, experts estimate that the actual number may be much higher due to unreported cases. Nearly 10% of all individuals suffering from glaucoma eventually experience serious vision impairments; nonetheless, almost none is likely to attain complete blindness. As per the Federal Statistical Office (Destatis), 16.2 million people in Germany were aged 67 and above by the end of 2021, and the number is projected to rise to 21.6 million by 2060. The probability of developing glaucoma and other eye diseases is likely to increase with aging. Thus, a significant prevalence of glaucoma due to the surging geriatric population propels the demand for glaucoma therapeutics across Germany.

Europe Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

Europe Glaucoma Therapeutics Market Segmentation

The Europe glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the Europe glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the Europe glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the Europe glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the Europe glaucoma therapeutics market is segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Germany dominated the Europe glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Europe glaucoma therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Europe Glaucoma Therapeutics Market - Key Market Dynamics

  • 4.1 Glaucoma Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Mounting Incidence of Glaucoma Disease
    • 4.2.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
  • 4.3 Market Restraints
    • 4.3.1 Medication Regimen Compliance Issues
  • 4.4 Market Opportunities
    • 4.4.1 Development of Wearable Technologies
  • 4.5 Future Trends
    • 4.5.1 Development of Novel Drug Delivery Methods
  • 4.6 Impact of Drivers and Restraints:

5. Glaucoma Therapeutics Market - Europe Analysis

  • 5.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • 5.2 Glaucoma Therapeutics Market Forecast Analysis

6. Europe Glaucoma Therapeutics Market Analysis - by Drug Class

  • 6.1 Beta Blockers
    • 6.1.1 Overview
    • 6.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.2 Alpha Adrenergic Agonists
    • 6.2.1 Overview
    • 6.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Prostaglandins Analogues
    • 6.3.1 Overview
    • 6.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Overview
    • 6.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.5 Combination Drugs
    • 6.5.1 Overview
    • 6.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Glaucoma Therapeutics Market Analysis - by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Overview
    • 7.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Overview
    • 7.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Others
    • 7.3.1 Overview
    • 7.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Glaucoma Therapeutics Market Analysis - by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Overview
    • 8.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Retail Pharmacy
    • 8.2.1 Overview
    • 8.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Online Pharmacy
    • 8.3.1 Overview
    • 8.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Glaucoma Therapeutics Market - Country Analysis

  • 9.1 Europe
    • 9.1.1 Europe: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
      • 9.1.1.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.2 Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.2.1 Germany: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.2.2 Germany: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.2.3 Germany: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.3 France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.3.1 France: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.3.2 France: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.3.3 France: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.4 United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.4.1 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.4.2 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.4.3 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.5 Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.5.1 Italy: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.5.2 Italy: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.5.3 Italy: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.6 Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.6.1 Spain: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.6.2 Spain: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.6.3 Spain: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.7 Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.7.1 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.7.2 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.7.3 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

10. Glaucoma Therapeutics Market - Industry Landscape

  • 10.1 Growth Strategies in Glaucoma Therapeutics Market
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview

11. Company Profiles

  • 11.1 Alcon AG
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 AbbVie Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Bausch & Lomb Inc
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Viatris Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Novartis AG
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Sun Pharmaceutical Industries Ltd
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Teva Pharmaceutical Industries Ltd
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Thea Pharma Inc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Santen Pharmaceutical Co., Ltd.
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Glaucoma Therapeutics Market Segmentation
  • Table 2. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 4. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 5. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 6. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Country
  • Table 7. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 8. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 9. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 10. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 11. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 12. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 13. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 14. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 15. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 16. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 17. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 18. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 19. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 20. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 21. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 22. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 23. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 24. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 25. Recent Organic Growth Strategies in Glaucoma Therapeutics Market
  • Table 26. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market
  • Table 27. Glossary of Terms

List Of Figures

  • Figure 1. Europe Glaucoma Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • Figure 4. Glaucoma Therapeutics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 5. Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 6. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Glaucoma Therapeutics Market Share (%) - by Indication (2023 and 2031)
  • Figure 12. Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Glaucoma Therapeutics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 16. Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Europe Glaucoma Therapeutics Market, by Key Country - Revenue (2023) (US$ Million)
  • Figure 20. Europe: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 21. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Growth Strategies in Glaucoma Therapeutics Market